TickerTalks
Browse all tickers →
TickerTalks›$DFTX
DFDFTX

Definium Therapeutics, Inc.

$DFTX·$5.0B·Biotechnology·Healthcare
$38.09+0.2%YTD+213.5%1Y+319.4%
Mentions · last 7 days
2026-08-28: 7 posts2026-08-29: 5 posts2026-08-30: 2 posts2026-08-31: 21 posts2026-09-01: 17 posts2026-09-02: 13 posts2026-09-03: 5 posts70
Price updated 2h ago·X counts updated 1d ago
DFDFTX
$DFTXDefinium Therapeutics, Inc.
$38.09+0.24%70 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $DFTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-09-03

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Clinical-stage neuropsych biotech with a positive Phase 3 topline for its lead LSD-based GAD program and a rolling NDA on deck.

Definium Therapeutics is a clinical-stage neuropsych bet whose Phase 3 Voyage readout landed positive, moving the story from binary trial risk into a regulatory-and-commercial setup that the tape is already trying to price.

  • Market cap is about $5B with the stock at $38.90, up 213% year-to-date and 326% over the last twelve months, so a very significant portion of a successful launch is already reflected in the equity.
  • There is effectively zero revenue with recent quarterly EPS at -$0.71 and no gross or operating margin to reference, confirming the business is entirely pipeline-and-regulation right now.
  • The last four earnings prints missed consensus by wide margins on burn, most recently 166% below expectations, so cash burn is running notably ahead of sell-side models.
  • The stock sits at about 74% of its 52-week range, roughly 11% below the 50-day but 58% above the 200-day moving averages with a beta of 2.3, the coiled setup ahead of a specific regulatory milestone.

The Phase 3 Voyage positive readout for DT120 in generalized anxiety plus reported rolling NDA coordination with peers like CMPS and ATAI keeps the FDA path central, and into Q3 earnings on 2026-11-05 the important question is whether NDA-timing commentary and any partnership or financing news arrive before the next scheduled cash burn does.

What to watch: Q3 earnings on 2026-11-05 for NDA timing, any partnership or licensing announcement on DT120, cash runway update given widening burn, and follow-on data from Phase 3 Voyage subgroups.

On the calendar: 2026-11-05 — Q3 earnings and NDA-timing update

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment⚠14 posts analyzed · as of 2026-09-03 · top-engagement diverged

Definium Therapeutics — Stifel reiterated Buy with $60 PT ahead of second Ph3 GAD readout later this month. Bulls flagging joint MDD/GAD NDA filing potential. But heavy Oct $37 put activity (~$800K to $1M+) suggests bearish/hedging positioning approaching 80% gains. Chart at 0.786 log fib. Genuine split on the binary catalyst.

Read the AI verdict + X sentiment for $DFTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing psychedelic-based therapies (synthetic LSD derivative MM120) for anxiety and ADHD.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $DFTX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $DFTX

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+52.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-10.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-60.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-102%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-1.44$-0.54-166.2%
Q1 2026May 7, 2026$-0.71$-0.47-51.1%
Q4 2025Feb 26, 2026$-0.51$-0.48-5.4%
Q3 2025Nov 6, 2025$-0.78$-0.52-50.0%
Next earningsThu, Nov 5·consensus EPS $-0.54

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.71$-42.6M
Q4 FY25$0———$-0.51$-41.9M
Q3 FY25$0———$-0.78$-29.6M
Q2 FY25$0———$-0.50$-29.6M

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$2.19-$2.43 – -$2.030
FY27$32.1M$5.9M – $141.6M-$1.59-$2.25 – -$1.059
FY28$242.3M$14.0M – $1.2B-$0.58-$2.20 – $4.5713
FY29$559.0M$102.2M – $2.5B$1.18-$0.07 – $6.4212
FY30$955.6M$174.7M – $4.2B$3.23-$0.20 – $17.556

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.71%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-13.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+53.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 128.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.265-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 25Mark SullivanChief Legal Officer13.0K sh$586KSellJun 25Matthew T. WileyChief Commercial Officer2.9K sh$129KSellJun 25Brandi RobertsCFO3.0K sh$136KSellJun 25Robert BarrowCEO29.2K sh$1.3MSellJun 25Daniel KarlinChief Medical Officer10.0K sh$452KSellMar 25Robert BarrowCEO24.4K sh$451KSellMar 25Mark SullivanChief Legal Officer10.7K sh$198KSellMar 25Daniel KarlinChief Medical Officer8.0K sh$148K
+ 16 other (16 awards) in window

See when $DFTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 128-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Definium Therapeutics, Inc. (DFTX), a British Columbia-incorporated clinical-stage company listed on Nasdaq, announced on August 12, 2026, positive topline data from its Phase 3 Voyage study of DT120 ODT for the treatment of generalized anxiety disorder (GAD). The company simultaneously posted a detailed data presentation to its website and filed the press release as Exhibit 99.1 and the presentation as Exhibit 99.2. A successful Phase 3 readout in GAD is a significant clinical and regulatory milestone, as it could support a New Drug Application submission to the FDA. Generalized anxiety disorder is a large and underserved market, giving a positive Phase 3 result substantial commercial implications if the data hold up to regulatory scrutiny. CEO Robert Barrow signed the filing, and the positive trial outcome makes DFTX a name to watch for potential partnership or approval catalysts in the near term.

8-KMaterial agreementJun 248-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

Definium Therapeutics entered an underwriting agreement on June 23, 2026 for a public offering of 20,588,236 common shares at $34.00/share (prior close $36.18). The underwriter greenshoe of 3,088,235 shares was exercised in full on June 24, 2026. Gross proceeds including greenshoe are ~$805M; net proceeds ~$758M, earmarked for R&D, potential commercialization of DT120 ODT, and working capital. Material — a major capital raise at a ~6% discount to market; significant dilution for existing shareholders.

424B5Prospectus supplement (offering)Jun 24424B5
AI summary

Definium Therapeutics filed a 424B5 prospectus supplement on June 23, 2026 for an offering of 20,588,236 common shares at $34.00/share, with a 3,088,235-share overallotment option. Gross proceeds of ~$700M base ($805M with full greenshoe); underwriting discounts of ~$40.3M base ($46.3M with greenshoe). Bookrunners: J.P. Morgan, Jefferies, Leerink Partners, BofA Securities. Material dilution event — confirms pricing and terms of the large equity raise at a discount to market.

424B5Prospectus supplement (offering)Jun 22424B5
AI summary

Definium Therapeutics, Inc. filed a preliminary 424B5 prospectus supplement for a $500M public offering of common shares and pre-funded warrants (plus a $75M overallotment option), with shares last trading at $24.48 on June 18, 2026 and per-share pricing still to be determined. Bookrunners include J.P. Morgan, Jefferies, Leerink Partners, and BofA Securities. A large, immediately dilutive raise for an emerging growth therapeutics company, appearing concurrent with positive Phase 3 MDD data.

8-KPress release / Reg FDJun 228-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Definium Therapeutics, Inc. announced positive topline data on June 22, 2026 from its Phase 3 'Emerge' study of DT120 ODT (oral dissolving tablet) for the treatment of major depressive disorder, simultaneously posting a data presentation on its website. Specific efficacy metrics (primary endpoint results, p-values, effect size) are in the attached press release (Exhibit 99.1) and presentation (Exhibit 99.2). Positive Phase 3 MDD data is a highly material, potentially transformative clinical milestone signaling regulatory submission eligibility, concurrent with Definium's $500M equity raise.

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Definium Therapeutics, Inc. held its 2026 Annual General and Special Meeting on June 11, 2026. Shareholders approved an amendment to the 2025 Equity Incentive Plan adding 5,000,000 common shares for issuance; director elections and other standard proposals also passed. The 5M share plan expansion is the material disclosure — a meaningful dilution event for a small therapeutics company, reflecting typical early-stage equity compensation requirements.

+ 13 other (3 13Gs · 3 routine 8-Ks · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Definium Therapeutics Announces New Employee Inducement Grantsbusinesswire.com·4d agoDefinium Therapeutics to Participate at Upcoming Investor Conferences and Eventsbusinesswire.com·10d agoThis Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com·18d agoDefinium Therapeutics Announces New Employee Inducement Grantsbusinesswire.com·18d agoDefinium Therapeutics' DT120 Meets Phase III Goals in GAD Studymarketbeat.com·23d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$MRNA$ALT$NWBO$SLS$RARE$IBRX$ABCL
Voices on X · top 10 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport